📌 Update: The Cash-Rich Biotech Case for Private Wealth. Beyond crowded technology trades, this established biotech offers high-net-worth investors growth backed by earnings and financial strength. Third-quarter revenue rose 36% to $5.1 billion, while adjusted EPS jumped 70% to $20.07. With $2.9 billion in nine-month free cash flow and $16.2 billion in net cash and marketable securities, it has substantial firepower to fund expansion
🔷 Featured allocation: US$80,000 | Four years
At an assumed annual return of 12%, compounded annually, US$80,000 would grow to approximately US$125,881.55—a potential gain of US$45,881.55.
Explore Our Investment Plans
🔴 US$250,000+ | Five-year term
Target: 0.5% monthly income plus 15% annually.
At an assumed annual return of 15% PLUS 0.5% per month compounded annually, US$250,000 would grow to approximately US$678,254.86—a potential gain of US$427,254.86
🟡 US$100,000+ | Two-year term
Target: 0.5% monthly income plus 11% annually.
At an assumed annual return of 11% PLUS 0.5% per month compounded annually, US$100,000 would grow to approximately US$138,877.36—a potential gain of US$38,877.36
🟠 US$50,000 | Four-year term
Proposed annual return: 9%.
At an assumed annual return of 9% US$50,000 would grow to approximately US$70,579.08—a potential gain of US$38,877.36
🔵 $1M | 2 years – Targeted: 0.5% monthly income plus 21% annually.
At an assumed annual return of 21% PLUS 0.5% per month compounded annually, US$1M would grow to approximately US$1,516.706 —a potential gain of US$516,706
WhatsApp: bit.ly/Alpha-Binwani-Capital
Website: alphabinwanicapital.com
LinkedIn: bit.ly/Alpha-Binwani-Capital-LinkedIn
Newsletter: bit.ly/FreeAlphaNewsletter
#BiotechInvesting #PrivateWealth #WealthManagement #HighNetWorth #HealthcareInvesting #GrowthInvesting #FreeCashFlow #EarningsGrowth #StrongBalanceSheet
